GUCY2C and irritable bowel syndrome: In contrast to expectations, IBD patients and an experimental colitis model showed downregulation of GC-C and its ligands in response to antecedent or concomitant inflammatory stimuli, implying that direct treatment with uroguanylin mimetic drugs can reduce inflammatory cytokines and play a protective role in inflammation (251).